Semaglutides: A Leading Driver Behind Impact Of Diabetes Prevalence On Semaglutides Market Growth Market Expansion in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Semaglutides Industry Market Size Be by 2025?
In recent times, there has been a rapid growth in the market size of semaglutides. Predictions indicate that it will expand from $23.07 billion in 2024 to $26 billion in 2025, showcasing a compound annual growth rate (CAGR) of 12.7%. The growth observed in the historic period is due to factors such as lifestyle changes leading to the widespread occurrence of diabetes, increased funding towards research and development, escalated healthcare expenditure, pharmaceutical companies broadening their reach to developing regions, and a rising acceptance towards injectable treatments.

What's the Long-Term Growth Forecast for the Semaglutides Market Size Through 2029?
Expectations are high for a significant expansion of the semaglutides market in the coming years, as it's set to surge to $41.4 billion in 2029 with a compound annual growth rate (CAGR) of 12.3%. This growth can be tied to several factors in the forecast period such as the escalating global prevalence of diabetes, enhanced understanding of diabetes treatment and management, the need for more effective therapies with reduced side effects, government policies endorsing diabetes treatment and an aging population which brings about a higher incidence of diabetes. Key trends leading the way in this period include the incorporation of digital health, the application of artificial intelligence and machine learning, the rise in telemedicine and remote monitoring needs, advances in wearable technology, increased demand for 3D printing, and the utilization of blockchain for managing supply chains.

View the full report here:
https://www.thebusinessresearchcompany.com/report/semaglutides-global-market-report

What Are the Key Growth Drivers Fueling the Semaglutides Market Expansion?
The semaglutide market is projected to expand due to the escalating prevalence of diabetes. Diabetes-a persistent disease that involves high blood glucose levels due to the body's inability to adequately produce or utilize insulin-is growing as a result of increased obesity, inactive lifestyles, and poor dietary routines. Semaglutide assists in controlling diabetes by imitating the GLP-1 hormone, which promotes the secretion of insulin, diminishes the release of glucagon, and hinders gastric emptying. This helps in reducing blood glucose levels and promotes weight loss. For example, Diabetes Canada, a non-profit organization based in Canada, reported that in February 2023, around 2.4 million Canadians were living with diabetes or prediabetes. This figure is anticipated to reach 3 million in 2033. Consequently, the escalating prevalence of diabetes is fuelling the expansion of the semaglutide market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18720&type=smp

What Are the Key Trends Driving Semaglutides Market Growth?
Leading corporations in the semaglutides industry are putting resources into the development of innovative products such as the GLP-1 receptor analogue. The aim is to amplify the effectiveness of diabetes and obesity therapies, minimize adverse reactions, upgrade patient compliance, and implement patient-specific therapeutic strategies through advanced delivery systems. The GLP-1 receptor analogue is a manufactured peptide that imitates the functions of glucagon-like peptide-1 (GLP-1), promoting insulin production and managing blood sugar levels in the treatment of diabetes. For instance, in January 2022, Novo Nordisk India, an Indian pharmaceutical specialist, introduced an orally-administered semaglutide which is expected to transform diabetes management. Previously, semaglutide, a GLP-1 receptor analogue used in diabetes treatment, was only available in injectable format. This represents the first example of the drug being created in an oral form. The oral semaglutide incorporates the GLP-1RA semaglutide and an absorption promoter known as SNAC to protect semaglutide from breakdown in the stomach - a usual problem for peptides - while simultaneously enhancing its absorption.

How Is the Semaglutides Market Segmented?
The semaglutides market covered in this report is segmented -

1) By Brands: Ozempic, Wegovy, Rybelsus
2) By Route Of Administration: Oral, Injection
3) By Application: Type 2 Diabetes, Obesity Management
4) By End-User: Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:
1) By Ozempic: Pen Injection (Auto-Injector), Prefilled Pens (Dosages 0.25mg, 0.5mg, 1mg, 2mg)
2) By Wegovy: Subcutaneous Injection (Auto-Injector), Prefilled Pens (Dosages 0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg)
3) By Rybelsus: Oral Tablets (Dosages Of 3mg, 7mg, 14mg)

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=18720&type=smp

Which Companies Are Leading the Charge in Semaglutides Market Innovation?
Major companies operating in the semaglutides market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis International AG, Takeda Pharmaceutical Company Limited, GlaxoSmithKline Plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Cipla Limited, Dr. Reddy's Laboratories Ltd., Biocon Limited, Hanmi Pharmaceutical Co. Ltd., Intarcia Therapeutics Inc., Adocia SA

Which Regions Are Leading the Global Semaglutides Market in Revenue?
North America was the largest region in the semaglutides market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the semaglutides market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18720

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.